ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty

Vatanabe, Izabela Pereira; Pedroso, Renata Valle; Manzine, Patrícia Regina; Chagas, Marcos Hortes Nisihara; Fabrício, Daiene de Morais; Grigoli, Marina Mantellatto; Naves, Marina Araújo; Pott-Jr, Henrique; Cominetti, Márcia Regina

doi:10.1016/j.exger.2021.111303

Cited by 7 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study reported a decrease in ADAM10 levels in PLTs associated with MCI and AD, suggesting that this reduction could serve as a potential biomarker for these conditions [138]. Similar findings were observed in both MCI and AD cases.…”

Section: The Role Of Platelets In Mild Cognitive Impairmentsupporting

confidence: 56%

Platelet Dynamics in Neurodegenerative Disorders: Investigating the Role of Platelets in Neurological Pathology

Cadoni,

Coradduzza,

Congiargiu

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Neurological disorders, particularly those associated with aging, pose significant challenges in early diagnosis and treatment. The identification of specific biomarkers, such as platelets (PLTs), has emerged as a promising strategy for early detection and intervention in neurological health. This systematic review aims to explore the intricate relationship between PLT dynamics and neurological health, focusing on their potential role in cognitive functions and the pathogenesis of cognitive disorders. Methods: Adhering to PRISMA guidelines, a comprehensive search strategy was employed in the PubMed and Scholar databases to identify studies on the role of PLTs in neurological disorders published from 2013 to 2023. The search criteria included studies focusing on PLTs as biomarkers in neurological disorders, their dynamics, and their potential in monitoring disease progression and therapy effectiveness. Results: The systematic review included 104 studies, revealing PLTs as crucial biomarkers in neurocognitive disorders, acting as inflammatory mediators. The findings suggest that PLTs share common features with altered neurons, which could be utilised for monitoring disease progression and evaluating the effectiveness of treatments. PLTs are identified as significant biomarkers for detecting neurological disorders in their early stages and understanding the pathological events leading to neuronal death. Conclusions: The systematic review underscores the critical role of PLTs in neurological disorders, highlighting their potential as biomarkers for the early detection and monitoring of disease progression. However, it also emphasises the need for further research to solidify the use of PLTs in neurological disorders, aiming to enhance early diagnosis and intervention strategies.

show abstract

Section: The Role Of Platelets In Mild Cognitive Impairmentsupporting

confidence: 56%

Platelet Dynamics in Neurodegenerative Disorders: Investigating the Role of Platelets in Neurological Pathology

Cadoni,

Coradduzza,

Congiargiu

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…A study showed that for individuals within a wide age range and particularly among the elderly, the platelet count gradually decreases with aging 41 . Another study found that thromboplastin and hormone metalloproteinase (ADAM10) levels may be associated with mild cognitive impairment (MCI) and physical frailty, with platelet ADAM10 levels decreasing under conditions of MCI and physical frailty 42 . Therefore, we can hypothesize that a higher platelet count within the normal range is associated with a lower the risk of frailty in elderly patients with OSAS, and the speci c underlying pathophysiology needs further exploration.…”

Section: Discussionmentioning

confidence: 99%

Association analysis of frailty with obstructive sleep apnea syndrome in elderly patients – A Multicenter Cohort Study

Xue

Gao

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective We assessed the incidence of frailty and identified the independent risk factors for the occurrence of frailty in elderly patients with obstructive sleep apnea syndrome (OSAS), which aims to provide a reference for the clinical treatment of OSAS and frailty.Methods We selected 1006 elderly patients with OSAS diagnosed using polysomnographic (PSG) between January 2015 and October 2017. We divided the patients into the non-frailty group (n = 731) and the frailty group (n = 275) based on the FRAIL scale score, compared the difference between the two groups. Multivariate cox regression analysis was used to identify the factors affecting the onset of frailty among elderly patients with OSAS.Results༚ 275 patients experienced frailty, yielding an incidence of 27.34%. Multivariate cox regression analysis showed that age(HR = 1.058, 95% CI:1.043–1.074, P < 0.001), constipation(HR = 1.490, 95%CI: 1.101–2.018, P = 0.010), carotid atherosclerosis (CA)(HR = 1.739, 95% CI: 1.299–2.330, P < 0.001), and renal insufficiency (RI)(HR = 1.878, 95% CI: 1.177–2.996, P = 0.008) are independent risk factors for frailty in elderly patients with OSAS. And platelet count(PLTC)(HR = 0.998, 95% CI: 0.996-1.000, P = 0.040), the mean arterial oxygen saturation(MSaO2)(HR = 0.950, 95% CI: 0.918–0.984, P = 0.005) are protect factors.Conclusion The incidence of frailty among elderly patients with OSAS is relatively high, and it was significantly higher in patients with severe OSAS than in those with mild or moderate OSAS. Age, constipation, CA, and RI are independent risk factors, whereas mean oxygen saturation and platelet count are protective factors for frailty in elderly patients with OSAS.

show abstract

“…This study analyzed data from community-dwelling older adults (n = 88) aged 60 or more recruited from primary (e.g., family health units) and secondary (e.g., specialty centers) care services in a municipality of São Carlos/Brazil. This is a secondary analysis of a previously investigated population whose characteristics were described elsewhere [23][24][25]. Participants were divided into three different groups according to their neurocognitive status and classified as group 1: CU (n = 31), group 2: MCI (n = 27), and group 3: AD (n = 30).…”

Section: Methodsmentioning

confidence: 99%

Plasma ADAM10 Levels and Their Association with Alzheimer’s Disease Diagnosis in Older Adults with Fewer Years of Formal Education

Pelegrini,

da Silva,

Grigoli

et al. 2024

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

Introduction: Low educational attainment is a potential risk factor for Alzheimer’s disease (AD) development. Alpha-secretase ADAM10 plays a central role in AD pathology, attenuating the formation of beta-amyloid peptides and, therefore, their aggregation into senile plaques. This study seeks to investigate ADAM10 as a blood-based biomarker in mild cognitive impairment (MCI) and AD in a diverse group of community-dwelling older adults, focusing on those with limited educational attainment. Methods: Participants were recruited from public health services. Cognition was evaluated using MMSE and ACE-R batteries. Blood samples were collected to analyze plasma ADAM10 levels. A logistic regression was conducted to verify the influence of plasma ADAM10 on the AD diagnosis. Results: Significant differences in age, years of education, prescribed medications, and cognitive test scores were found between the MCI and AD groups. Regarding cognitive performance, both ACE-R and MMSE scores displayed significant differences between groups, with post-hoc analyses highlighting these distinctions, particularly between AD and cognitively healthy individuals. Elevated plasma ADAM10 levels were associated with a 4.5-fold increase in the likelihood of a diagnosis of MCI and a 5.9-fold increase in the likelihood of a diagnosis of AD. These findings suggest that ADAM10 levels in plasma serve as a valuable biomarker for assessing cognitive status in older individuals with low education attainment. Conclusion: This study underscores the potential utility of plasma ADAM10 levels as a blood-based biomarker for cognitive status, especially in individuals with low educational backgrounds, shedding light on their relevance in AD development and diagnosis.

show abstract

ADAM10: Biomarker of mild cognitive impairment but not of cognitive frailty

Cited by 7 publications

References 41 publications

Platelet Dynamics in Neurodegenerative Disorders: Investigating the Role of Platelets in Neurological Pathology

Platelet Dynamics in Neurodegenerative Disorders: Investigating the Role of Platelets in Neurological Pathology

Association analysis of frailty with obstructive sleep apnea syndrome in elderly patients – A Multicenter Cohort Study

Plasma ADAM10 Levels and Their Association with Alzheimer’s Disease Diagnosis in Older Adults with Fewer Years of Formal Education

Contact Info

Product

Resources

About